Takeda adds one more late-stage treatment to its growing roster of celiac drugs
Whatever happens with Takeda’s determined campaign to tackle celiac disease from all sides, no one will ever be able to fault them for a lack of dedication to the cause.
This morning, the global player joined hands with Zedira and Dr. Falk Pharma GmbH on a Phase IIb celiac drug dubbed ZED1227/TAK-227, giving Takeda dibs on the big US market plus a string of countries outside Europe.
Takeda, though, is anything but a newcomer when it comes to fighting gluten intolerance, a food allergy that currently can only be treated with a strict diet that avoids all wheat, barley and rye. The company has inked a range of alliances to build up a pipeline of a well-advanced set of drugs for celiac.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.